



Christopher Horan Joins SanBio as Corporate Officer and Chief Technical Operations Officer

Mountain View, Calif.—July 15, 2020— The SanBio Group (SanBio Co., Ltd. and SanBio, Inc.), a scientific leader in regenerative medicine for neurological disorders, today announced the appointment of Christopher Horan as Corporate Officer of SanBio Co., Ltd. and Chief Technical Operations Officer of SanBio, Inc.

Chris joins SanBio from Dermira where he spent two years as Chief Technical Operations Officer, growing a high-performing team to launch the company's first commercial product. In addition, Chris led the effort to prepare lebrikizumab, a monoclonal antibody, for Phase 3 trials and commercial filing. Chris had a key role in supporting Dermira's successful acquisition by Eli Lilly in early 2020. Prior to Dermira, Chris spent nearly 14 years at Genentech (a member of the Roche Group) in roles of increasing responsibility within its Operational Excellence, Supply Chain, Procurement and Technical Operations functions. He served as Senior Vice President, Global Product and Supply Chain Management, where he led a team supplying all Roche biopharma products worldwide. Prior to Genentech, he worked for Merck & Company in global roles across Engineering, Manufacturing and Operational Excellence. Chris holds a B.E. in engineering from the Stevens Institute of Technology in New Jersey.

In Japan, the SanBio Group is currently working toward applying for manufacturing and marketing approval of SB623 for the treatment of chronic motor deficit resulting from traumatic brain injury (TBI). SanBio plans to submit this application during the fiscal year ending January 31, 2021 (February 1, 2020–January 31, 2021). Further, SanBio plans to initiate a Phase 3 clinical trial of SB623 for the same indication by the end of the fiscal year ending January 31, 2021. In his newly created role, Chris will oversee pharmaceutical, process and analytical development, supply chain, contract manufacturing, and quality assurance as SanBio prepares to file SB623 in Japan and the U.S. for the treatment of traumatic brain injury, and to advance the development of a pipeline of regenerative cell medicines.

"I am thrilled to be joining SanBio at a critical time for the company, as we continue to develop our manufacturing and supply chain capabilities in preparation for the filing and

potential launch of SB623,” said Horan. “SanBio’s pioneering science and patient-driven culture is a great fit and strong attraction for me. I look forward to contributing to the company’s long term success.”

“Chris brings a strong track record of leadership to SanBio and we are delighted that he is joining at a critical moment for the company, as we prepare to bring our first treatment to patients,” said Keita Mori, founder, chairman and chief executive officer of SanBio.

“His broad experience leading all aspects of technical operations will ensure excellence as we execute on our development plans.”

About SanBio, Inc. (SanBio)

SanBio is a regenerative medicine company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research, development and clinical trials. Its proprietary cell-based investigational product, SB623, has been evaluated in a Phase 2b clinical trial for treatment of chronic motor deficit resulting from ischemic stroke, and in a Phase 2 clinical trial for treatment of chronic motor deficit resulting from traumatic brain injury. More information about SanBio, Inc. is available at <http://sanbio.com>.

###

For more information, contact:

SanBio Co., Ltd.

Management Administration

info@sanbio.jp